2315 fundamentals
BIOCYTOGEN PHARMACEUTICALS (BEIJING financial statements, including revenue, expenses, and profit
The total revenue of 2315 for the last semiannual is 618.29 M HKD, and it's 39.00% higher compared to the previous semiannual. The net income of H2 24 is 91.36 M HKD.
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: HKD
TTM